Cognitive deficits are a core aspect of psychotic disorders; however, it is not clear to which
extent different pharmacological treatments could distinctly impact these outcomes. Hence …

These updated guidelines are based on a first edition of the World Federation of Societies of
Biological Psychiatry Guidelines for Biological Treatment of Schizophrenia published in …

Originally published in February 2004. This guideline is more than 5 years old and has not
yet been updated to ensure that it reflects current knowledge and practice. In accordance …

PSILOCYBIN, an indoleamine hallucinogen, produces a psychosis-like syndrome in
humans that resembles first episodes of schizophrenia. In healthy human volunteers, the …

OBJECTIVE: Memory impairment is well documented in schizophrenia. Less is known,
however, about the exact magnitude, pattern, and extent of the impairment. The effect of …

The treatment of schizophrenia has evolved over the past half century primarily in the
context of antipsychotic drug development. Although there has been significant progress …

This report reviews the state of the literature and opportunities for research related to
“executive control function”(ECF). ECF has recently been separated from the specific …

Working memory (WM) deficit is a cardinal cognitive symptom of schizophrenia, but the
differences among the tasks and measures used to assess WM make it difficult to compare …

Objective To investigate the effect of second‐generation antipsychotics on cognitive function
in patients diagnosed with schizophrenia or schizoaffective disorder. Method Multiple …

Cognitive function is markedly impaired in most patients with schizophrenia. Antecedents of
this impairment are evident in childhood. The cognitive disability is nearly fully developed at …